Pompiliu Piso1,2, Kathrin Stierstorfer3, Michael Gerken3, Monika Klinkhammer-Schalke3. 1. Department of General and Visceral Surgery, Barmherzige Brueder Hospital Regensburg, Pruefeninger Str. 86, 93049, Regensburg, Germany. pompiliu.piso@barmherzige-regensburg.de. 2. Klinik für Allgemein- und Viszeralchirurgie, Krankenhaus Barmherzige Brueder Regensburg, Pruefeninger Str. 86, 93049, Regensburg, Germany. pompiliu.piso@barmherzige-regensburg.de. 3. Tumor Center - University Institute of Quality Assurance and Health Services Research, Am BioPark 9, 93053, Regensburg, Germany.
Abstract
BACKGROUND: Ever since Sugarbaker has established the cytoreductive surgery (CRS) in combination with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC), there is a chance of cure for selected patients with peritoneal metastases from colorectal cancer. Objective of this study was to investigate the benefit of CRS and HIPEC compared to other therapy options in patients with isolated synchronous and metachronous peritoneal metastases of colorectal origin in terms of long-term overall survival. METHODS: A retrospective population-based cohort study, including 370 patients diagnosed with isolated synchronous and metachronous peritoneal metastases of colorectal origin, was carried out. Therefore, data were acquired from the cancer registry at the Regensburg Tumor Center in Bavaria, Germany. Patients' overall survival (OAS) according to their therapy received was analyzed by means of Kaplan-Meier method and multivariable Cox regression. RESULTS: Overall median survival was 41.6 months for patients treated with CRS and HIPEC, compared with surgery and chemotherapy (24.0 months, log-rank p = 0.015), chemotherapy only (14.1 months, p < 0.001), surgery only (11.4 months, p < 0.001), and best supportive care (7.9 months, p < 0.001). This benefit persisted after adjustment for further risk factors in multivariable analysis. CONCLUSION: The effect of CRS and HIPEC stands out significantly in comparison to all other therapies. The multimodality approach should be a regular option for patients with isolated peritoneal metastases.
BACKGROUND: Ever since Sugarbaker has established the cytoreductive surgery (CRS) in combination with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC), there is a chance of cure for selected patients with peritoneal metastases from colorectal cancer. Objective of this study was to investigate the benefit of CRS and HIPEC compared to other therapy options in patients with isolated synchronous and metachronous peritoneal metastases of colorectal origin in terms of long-term overall survival. METHODS: A retrospective population-based cohort study, including 370 patients diagnosed with isolated synchronous and metachronous peritoneal metastases of colorectal origin, was carried out. Therefore, data were acquired from the cancer registry at the Regensburg Tumor Center in Bavaria, Germany. Patients' overall survival (OAS) according to their therapy received was analyzed by means of Kaplan-Meier method and multivariable Cox regression. RESULTS: Overall median survival was 41.6 months for patients treated with CRS and HIPEC, compared with surgery and chemotherapy (24.0 months, log-rank p = 0.015), chemotherapy only (14.1 months, p < 0.001), surgery only (11.4 months, p < 0.001), and best supportive care (7.9 months, p < 0.001). This benefit persisted after adjustment for further risk factors in multivariable analysis. CONCLUSION: The effect of CRS and HIPEC stands out significantly in comparison to all other therapies. The multimodality approach should be a regular option for patients with isolated peritoneal metastases.
Authors: Jan Franko; Qian Shi; Charles D Goldman; Barbara A Pockaj; Garth D Nelson; Richard M Goldberg; Henry C Pitot; Axel Grothey; Steven R Alberts; Daniel J Sargent Journal: J Clin Oncol Date: 2011-12-12 Impact factor: 44.544
Authors: C Pox; S Aretz; S C Bischoff; U Graeven; M Hass; P Heußner; W Hohenberger; A Holstege; J Hübner; F Kolligs; M Kreis; P Lux; J Ockenga; R Porschen; S Post; N Rahner; A Reinacher-Schick; J F Riemann; R Sauer; A Sieg; W Scheppach; W Schmitt; H J Schmoll; K Schulmann; A Tannapfel; W Schmiegel Journal: Z Gastroenterol Date: 2013-08-16 Impact factor: 2.000
Authors: Lieke G E M Razenberg; Valery E P P Lemmens; Victor J Verwaal; Cornelis J A Punt; Pieter J Tanis; Geert-Jan Creemers; Ignace H J T de Hingh Journal: Eur J Cancer Date: 2016-08-03 Impact factor: 9.162
Authors: Hidde J Braam; Thijs R van Oudheusden; Ignace H J T de Hingh; Simon W Nienhuijs; Djamila Boerma; Marinus J Wiezer; Bert van Ramshorst Journal: J Surg Oncol Date: 2014-03-12 Impact factor: 3.454
Authors: Geert A Simkens; Thijs R van Oudheusden; Hidde J Braam; Marinus J Wiezer; Simon W Nienhuijs; Harm J Rutten; Bert van Ramshorst; Ignace H de Hingh Journal: J Surg Oncol Date: 2016-01-12 Impact factor: 3.454
Authors: Joerg O W Pelz; Terence C Chua; Jesus Esquivel; Alexander Stojadinovic; Joerg Doerfer; David L Morris; Uwe Maeder; Christoph-Thomas Germer; Alexander G Kerscher Journal: BMC Cancer Date: 2010-12-22 Impact factor: 4.430
Authors: Christina Hackl; Peter Neumann; Michael Gerken; Martin Loss; Monika Klinkhammer-Schalke; Hans J Schlitt Journal: BMC Cancer Date: 2014-11-04 Impact factor: 4.430
Authors: Pinuccia Faviana; Laura Boldrini; Barbara Musco; Mauro Ferrari; Alfonso Greco; Lorenzo Fornaro; Gianluca Masi; Francesco Forfori; Sergio Ricci; Augusto Brogi; Fulvio Basolo; Alfredo Falcone; Angelo Gadducci; Piero Vincenzo Lippolis Journal: In Vivo Date: 2020 Jul-Aug Impact factor: 2.155
Authors: Alicja Bieńkowska; Weronika Kuźmicka; Olga Ciepiela; Justyn Ochocki; Maciej Małecki Journal: Biomed Res Int Date: 2020-02-08 Impact factor: 3.411